In the current study, we observed the anti-CRC functions of 5-FU in a dose-dependent manner as expected, whereas the overexpression of STK35 in CRC cells partially reversed these effects, such as the promotion of apoptosis, tumor growth inhibition, and survival improvement in an in vivo mouse model. The gene discussed is STK35; the disease is neoplasm.